Abstract

Synthesis of truncated androgen receptor (AR) splice variants has emerged as an important mechanism of prostate cancer (PCa) resistance to AR-targeted therapy and progression to a lethal castration-resistant phenotype. However, the precise role of these factors at this stage of the disease is not clear due to loss of multiple COOH-terminal AR protein domains, including the canonical nuclear localization signal (NLS) in the AR hinge region. Despite loss of this NLS, we show that diverse truncated AR variant species have a basal level of nuclear localization sufficient for ligand-independent transcriptional activity. Whereas full-length AR requires Hsp90 and importin-β for active nuclear translocation, basal nuclear localization of truncated AR variants is independent of these classical signals. For a subset of truncated AR variants, this basal level of nuclear import can be augmented by unique COOH-terminal sequences that reconstitute classical AR NLS activity. However, this property is separable from ligand-independent transcriptional activity. Therefore, the AR splice variant core consisting of the AR NH(2)-terminal domain and DNA binding domain is sufficient for nuclear localization and androgen-independent transcriptional activation of endogenous AR target genes. Indeed, we show that truncated AR variants with nuclear as well as nuclear/cytoplasmic localization patterns can drive androgen-independent growth of PCa cells. Together, our data demonstrate that diverse truncated AR species with varying efficiencies of nuclear localization can contribute to castration-resistant PCa pathology by driving persistent ligand-independent AR transcriptional activity.

Highlights

  • Truncated androgen receptor (AR) splice variants support castration-resistant prostate cancer

  • Truncated AR Variants with Diverse COOH-terminal Extensions Are Constitutively Nuclear Transcription Factors—The majority of AR transcriptional activity is mediated by the AR NH2-terminal domain (NTD) and deletion of the AR ligand binding domain (LBD) results in constitutive, ligandindependent activity [22]

  • Because castrationresistant PCa (CRPCa) is characterized by persistent AR transcriptional activity under conditions of Androgen depletion therapy (ADT), these findings indicate that AR variants consisting of the AR NTD and DNA binding domain (DBD) may contribute to disease progression regardless of the identity of their COOH-terminal extensions

Read more

Summary

Background

Truncated AR splice variants support castration-resistant prostate cancer. Results: The AR NTD/DBD core is sufficient for AR variants to access the nucleus, activate AR target genes, and support androgen-independent prostate cancer cell growth. The precise role of these factors at this stage of the disease is not clear due to loss of multiple COOH-terminal AR protein domains, including the canonical nuclear localization signal (NLS) in the AR hinge region Despite loss of this NLS, we show that diverse truncated AR variant species have a basal level of nuclear localization sufficient for ligand-independent transcriptional activity. These studies indicate that changes in AR splicing are important for clinical CRPCa progression and may drive resistance to therapies that require an intact AR LBD, including next-generation inhibitors such as abiraterone [12] It is unclear whether diverse truncated AR variants can activate the AR transcriptional program because many of these species are predicted to have lost the canonical AR nuclear localization signal (NLS) in the exon 4-encoded hinge region.

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call